These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 5231832)

  • 1. Consent for use of investigational new drugs on humans.
    Blasingame FJ
    Med Ann Dist Columbia; 1966 Dec; 35(12):685-6. PubMed ID: 5231832
    [No Abstract]   [Full Text] [Related]  

  • 2. Medical devices: procedures for investigational device exemptions.
    Fed Regist; 1978 May; 43(93):20725-57. PubMed ID: 10307350
    [No Abstract]   [Full Text] [Related]  

  • 3. Should combat troops be given the option of refusing investigational drug treatment?
    Ryan RP
    Food Drug Law J; 1997; 52(4):377-400. PubMed ID: 10346671
    [No Abstract]   [Full Text] [Related]  

  • 4. Human drugs and biologics; determination that informed consent is NOT feasible or is contrary to the best interests of recipients; revocation of 1990 interim final rule; establishment of new interim final rule. Food and Drug Administration, HHS. Interim final rule; opportunity for public comment.
    Fed Regist; 1999 Oct; 64(192):54180-9. PubMed ID: 11010702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA's new rule on treatment use and sale of investigational new drugs.
    Levine RJ
    IRB; 1987; 9(4):1-4. PubMed ID: 11649946
    [No Abstract]   [Full Text] [Related]  

  • 6. Medical devices; procedures for investigational device exemptions--Food and Drug Administration. Final rule.
    Fed Regist; 1980 Jan; 45(13):3732-59. PubMed ID: 10248822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA overview and current challenges in regulation of human subject protection. Food and Drug Administration.
    Nightingale SL
    J Int Assoc Physicians AIDS Care; 1997 Jan; 3(1):24-6. PubMed ID: 11363959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethical implications of withdrawal of experimental drugs at the conclusion of phase III trials.
    Roginsky MS; Handley A
    Clin Res; 1978 Dec; 26(6):384-8. PubMed ID: 10239695
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA seeks public comment on informed consent rules in combat situations.
    Hastings Cent Rep; 1997; 27(5):43. PubMed ID: 11645003
    [No Abstract]   [Full Text] [Related]  

  • 10. Obligations of clinical investigators of regulated articles--proposed establishment of regulations.
    Fed Regist; 1978 Aug; 43(153):35209-36. PubMed ID: 10237258
    [No Abstract]   [Full Text] [Related]  

  • 11. A lesson from Melos.
    Owen JA
    Hosp Formul; 1979 Feb; 14(2):127. PubMed ID: 10240142
    [No Abstract]   [Full Text] [Related]  

  • 12. Protection of human subjects: proposed establishment of regulations.
    Fed Regist; 1978 May; 43(88):19417-22. PubMed ID: 10307348
    [No Abstract]   [Full Text] [Related]  

  • 13. IRB review of adverse events in investigational drug studies.
    Prentice ED; Gordon B
    IRB; 1997; 19(6):1-4. PubMed ID: 11656910
    [No Abstract]   [Full Text] [Related]  

  • 14. Gulf War guinea pigs: is informed consent optional during war?
    Milner CA
    J Contemp Health Law Policy; 1996; 13(1):199-232. PubMed ID: 9068242
    [No Abstract]   [Full Text] [Related]  

  • 15. The investigational new drug application--who benefits?
    Freireich EJ
    Nat Clin Pract Oncol; 2006 Feb; 3(2):62-3. PubMed ID: 16462826
    [No Abstract]   [Full Text] [Related]  

  • 16. Walking a thin line: distinguishing between research and medical practice during Operation Desert Storm.
    Schuchardt EJ
    Spec Law Dig Health Care Law; 1993 Nov; (177):9-47. PubMed ID: 10130675
    [No Abstract]   [Full Text] [Related]  

  • 17. Standards for institutional review boards for clinical investigations: proposed establishment of regulations.
    Fed Regist; 1978 Aug; 43(153):5185-208. PubMed ID: 10237259
    [No Abstract]   [Full Text] [Related]  

  • 18. Proposal on waiver of informed consent poses major issues for research ethics.
    Maloney DM
    Hum Res Rep; 1997 Sep; 12(9):1-3. PubMed ID: 11660533
    [No Abstract]   [Full Text] [Related]  

  • 19. Pediatric priorities: legislative and regulatory initiatives to expand research on the use of medicines in pediatric patients.
    Labson MS
    J Health Care Law Policy; 2002; 6(1):34-72. PubMed ID: 15017951
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical pharmacology--a review. Federal Drug Regulations and their impact on clinical pharmacology.
    Pallasch TJ
    J Oral Ther Pharmacol; 1966 Sep; 3(2):136-48 concl. PubMed ID: 5340322
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.